知镜 Cognispect · 医学文献与研究工作台

Extending seasonal malaria chemoprevention to older children: a non-inferiority randomized controlled trial of Dihydroartemisinin-piperaquine as a policy alternative in Mali.

Toure M, Keita S, Kane F, Sanogo D, Sanogo I, Keita M, Sissoko IM, Diallo M, Coulibaly H, Cisse B, Konate D, Guindo I, Malle MA, Tangara CO, Diawara SI, Cissoko M, Sanogo V, Kone A, Niare S, Maiga A, Sogoba N, Hansonn HH, Alifrangis M, Diakite M, Shaffer JG, Doumbia S.
The Lancet regional health. Africa · 2026-08-13 · PMID 42808016

文献摘要

Background Seasonal malaria chemoprevention (SMC) with Sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) reduces malaria in children under five, but substantial burden remains among children 5-9 years. Emerging SP/AQ resistance and adherence challenges underscore the need for alternative regimens. Dihydroartemisinin-piperaquine (DHAPQ) is a promising option, although evidence from multi-season programmatic settings in the Sahel is limited. We aimed to evaluate the effectiveness and safety of DHAPQ compared with SPAQ when SMC was extended to children aged 3 months to 9 years. Methods We conducted a two-year, three-arm, cluster-randomized crossover trial in nine health-catchment clusters in Mali. Clusters received standard SPAQ SMC ( Findings Among 12,854 children, DHAPQ was non-inferior to extended-age SPAQ (HR = 0.7, 95% CI 0.6-0.9) and achieved higher intervention coverage, with no serious adverse events reported. Children aged 5-9 years had a lower hazard of clinical malaria than children younger than 5 years (HR = 0.9, 95% CI 0.8-0.9). Interpretation Extending SMC to children aged 5-9 years substantially reduced malaria burden. DHAPQ was safe, effective, and operationally feasible, supporting its consideration as an alternative to SPAQ where adherence or resistance threatens SMC effectiveness. Funding NIH/NIAID-ICEMR-WAF.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。